VolitionRX (VNRX) to Release Earnings on Monday

VolitionRX (NYSEAMERICAN:VNRX) will likely be posting its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.05) per share and revenue of $0.7140 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, April 3, 2026 at 4:00 PM ET.

VolitionRX Stock Performance

NYSEAMERICAN VNRX opened at $0.19 on Monday. The company has a fifty day simple moving average of $0.24 and a 200 day simple moving average of $0.36. The company has a market cap of $25.76 million, a P/E ratio of -0.83 and a beta of 1.34. VolitionRX has a 1 year low of $0.17 and a 1 year high of $0.94.

Analyst Ratings Changes

A number of research analysts have weighed in on VNRX shares. Maxim Group lowered shares of VolitionRX from a “buy” rating to a “hold” rating in a research report on Wednesday, December 3rd. D. Boral Capital reaffirmed a “buy” rating and issued a $3.00 price target on shares of VolitionRX in a research report on Wednesday, March 18th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Hold rating to the company. According to MarketBeat, VolitionRX currently has an average rating of “Buy” and a consensus price target of $2.50.

Institutional Investors Weigh In On VolitionRX

Hedge funds and other institutional investors have recently modified their holdings of the stock. Virtu Financial LLC increased its position in VolitionRX by 166.6% during the fourth quarter. Virtu Financial LLC now owns 108,581 shares of the medical research company’s stock worth $28,000 after acquiring an additional 67,848 shares during the period. Squarepoint Ops LLC bought a new stake in VolitionRX in the 4th quarter valued at $34,000. Jane Street Group LLC acquired a new stake in VolitionRX in the 4th quarter worth $28,000. Geode Capital Management LLC grew its position in VolitionRX by 9.8% in the 4th quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock worth $246,000 after purchasing an additional 85,816 shares during the last quarter. Finally, Armistice Capital LLC increased its holdings in shares of VolitionRX by 10.4% during the 3rd quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock worth $6,367,000 after purchasing an additional 887,351 shares during the period. Institutional investors and hedge funds own 8.09% of the company’s stock.

About VolitionRX

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.